Thomas Vedvick, Phd

Biography

Thomas Vedvick is the Vice President of Formulation and Process Development at IDRI. Tom's research interests are focused on the development of large scale protein purification and the characterization of proteins for vaccine development. In addition, Tom directs the exciting adjuvant formulation program at IDRI. He has more than 70 original articles, and holds 28 issued U.S. patents for diagnostics, vaccines, and therapeutics of infectious diseases and cancer.

Research Interest

Prior to joining IDRI, Tom worked at the Salk Institute Biotechnology Industrial Associates (SIBIA) where he led the protein purification and characterization laboratory. While at SIBIA he collaborated on the development of the Pichia pastoris recombinant protein expression system. Tom later left SIBIA to work at Telios Pharmaceuticals, where he developed peptide based products for wound healing. Tom then joined Corixa Corporation where he established a protein microsequencing facility and directed the process development group which focused on vaccines for infectious diseases and cancer. Afterwards, Tom spent two years working at LigoCyte pharmaceuticals, where he served as Director of Process Development and Project Leader in the Norovirus vaccine program. He led the development of purification methods, formulation, and cGMP contract manufacturing of the Norovirus,Virus Like Particles. This successful program was the first product that reached a phase I clinical trial for LigoCyte Pharmaceutical.